Lamisil DermGel gel

Country: Armenia

Language: English

Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Active ingredient:

terbinafine

Available from:

GlaxoSmithKline Consumer Healthcare S.A.

ATC code:

D01AE15

INN (International Name):

terbinafine

Dosage:

10mg/g

Pharmaceutical form:

gel

Units in package:

15g aluminium tube

Prescription type:

OTC

Authorization status:

Registered

Authorization date:

2020-01-09

Summary of Product characteristics

GSK Consumer Healthcare S.A.
CH-1260 Nyon, Switzerland
Global Drug Regulatory Affairs
LAMISIL DERMGEL
Terbinafine
SUMMARY OF PRODUCT CHARACTERISTICS
Property of GSK Consumer Healthcare S.A.
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of GSK Consumer Healthcare S.A.
GSK Consumer Healthcare S.A.
CONFIDENTIAL
Page 2
Summary of Product Characteristics
LamisilDermgel 1% Gel
CONTENTS
1.
NAME OF THE MEDICINAL PRODUCT
................................................................................
3
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
...................................................... 3
3.
PHARMACEUTICAL FORM
....................................................................................................
3
4.
CLINICAL PARTICULARS
......................................................................................................
3
4.1.
Therapeutic indications
..................................................................................................
3
4.2.
Posology and method of administration
.........................................................................
3
4.3.
Contra-indications
..........................................................................................................
4
4.4.
Special warnings and precautions for use
......................................................................
4
4.5.
Interactions with other medicinal products and other forms of
interaction ................... 4
4.6.
Pregnancy and lactation
..................................................................................................
4
4.7.
Effects on ability to drive and use machines
.................................................................. 4
4.8.
Undesirable effects
.........................................................................................................
4
4.9.
Overdose
.........................................................................................................................
5
5.
PHARMACOLOGICAL PROPE